GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Total Liabilities

Vectus Biosystems (ASX:VBS) Total Liabilities : A$0.84 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Total Liabilities?

Vectus Biosystems's Total Liabilities for the quarter that ended in Dec. 2023 was A$0.84 Mil.

Vectus Biosystems's quarterly Total Liabilities increased from Dec. 2022 (A$1.02 Mil) to Jun. 2023 (A$1.11 Mil) but then declined from Jun. 2023 (A$1.11 Mil) to Dec. 2023 (A$0.84 Mil).

Vectus Biosystems's annual Total Liabilities declined from Jun. 2021 (A$8.87 Mil) to Jun. 2022 (A$7.47 Mil) and declined from Jun. 2022 (A$7.47 Mil) to Jun. 2023 (A$1.11 Mil).


Vectus Biosystems Total Liabilities Historical Data

The historical data trend for Vectus Biosystems's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Total Liabilities Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial 3.92 8.64 8.87 7.47 1.11

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 7.47 1.02 1.11 0.84

Vectus Biosystems Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vectus Biosystems's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.076+(0.027+2.6888213877641E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.003)
=1.11

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=4.63-3.524
=1.11

Vectus Biosystems's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.808+(0+0.029
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.84

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=3.207-2.37
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems Total Liabilities Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines